Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 19, 2008

AstraZeneca Taps Cenix for RNAi Drug Discovery

  • Cenix BioScience will help AstraZeneca advance discovery activities and validate drug targets. Cenix will combine high-throughput (HT) applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells.

    The initial project will involve an HT-RNAi screen using an assay strategy codesigned with AstraZeneca to discover and validate oncology targets. Cenix will use Definiens’ Cellenger image-analysis platform to implement multiparametric microscopy-based assays. The company reports that this will lead to insights into cellular functions and loss-of-function phenotypes of analyzed genes.

    Cenix hopes to expand the collaboration beyond oncology into multiple projects, says Christophe Echeverri, CEO and CSO.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »